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Abstract
 
HLA class I polymorphism creates diversity in epitope specificity and T cell repertoire. We
show that HLA polymorphism also controls the choice of Ag presentation pathway. A single
amino acid polymorphism that distinguishes HLA-B
 
*
 
4402 (Asp116) from B
 
*
 
4405 (Tyr116)
permits B
 
*
 
4405 to constitutively acquire peptides without any detectable incorporation into
the transporter associated with Ag presentation (TAP)-associated peptide loading complex even
under conditions of extreme peptide starvation. This mode of peptide capture is less susceptible
to viral interference than the conventional loading pathway used by HLA-B
 
*
 
4402 that involves
assembly of class I molecules within the peptide loading complex. Thus, B
 
*
 
4402 and B
 
*
 
4405
are at opposite extremes of a natural spectrum in HLA class I dependence on the PLC for Ag
presentation. These findings unveil a new layer of MHC polymorphism that affects the generic
pathway of Ag loading, revealing an unsuspected evolutionary trade-off in selection for optimal
HLA class I loading versus effective pathogen evasion.
Key words: HLA • polymorphism • Ag presentation • tapasin • immune evasion
 
Introduction
 
Polymorphism in the HLA genes of the MHC is concen-
trated in the Ag-binding cleft and is thought to be maintained
by natural selection for pathogen immunity (1). Accordingly,
these polymorphisms probably provide a heterozygous ad-
vantage in presenting diverse ligands to T cells (1) and broad-
ening  the immune response to pathogens (2, 3). Some
polymorphisms also appear to affect generic aspects of Ag
presentation such as class I assembly and rate of transport to
the cell surface (4–12). Class I molecules first associate with
calnexin in the ER before complexing with 
 
 
 
2-microglobulin
and then calreticulin (13). Class I–peptide loading is facilitated
by tapasin, a molecule that brings the calreticulin–class I–
 
 
 
2m
complex into physical association with the heterodimeric
transporter associated with Ag presentation (TAP) (14) and
the thiol oxidoreductase ERp57, creating the PLC (13,
15). Tapasin also increases steady-state levels of TAP (16),
retains empty class I molecules in the ER (11, 17, 18), and
partially facilitates peptide loading by stabilizing the empty
class I complexes without bridging them to the TAP complex
(16). Tapasin is transiently disulfide linked to ERp57 in the
PLC, suggesting that disulfide bond isomerization may play
a role in peptide loading (19). These functions of tapasin
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optimize peptide loading of class I molecules, producing a
more stable cohort of class I–peptide complexes for presen-
tation to T cells (13, 18, 20).
There is a spectrum in class I dependency on tapasin for
loading of peptide in the ER (4, 6, 8–10, 17). Most class I
allotypes, such as HLA-B
 
*
 
4402 (6, 17), HLA-B8 (6), and
B
 
*
 
1510 (8), associate strongly with the TAP and are highly
dependent on tapasin for effective Ag presentation (6, 21).
Other class I molecules, such as HLA-B
 
*
 
2705 (6), HLA-
B
 
*
 
1501, B
 
*
 
1518 (8), and RT1.A
 
u
 
 (7), can load peptides
without incorporation into the PLC, even though most of
these allotypes are normally incorporated into the PLC in
the presence of tapasin (6, 7).
The structural features of class I molecules that confer
the capacity for peptide loading without TAP assembly ap-
pear to involve the F pocket of the Ag binding cleft, partic-
 
Table II.
 
 Crystal Structure Refinement Statistics
 
B
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4405/EEFGRAFSF B
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4403/EEPTVIKKY
Nonhydrogen atoms
Protein 3,166 3,162
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Table I.
 
 Crystal Structure Data Collection
 
B
 
*
 
4405/EEFGRAFSF B
 
*
 
4403/EEPTVIKKY
Temperature 100 K 100 K
Space Group P
 
2
 
1
 
2
 
1
 
2
 
1
 
P
 
2
 
1
 
2
 
1
 
2
 
1
 
Cell dimensions (Å) (
 
a, b, c
 
) 50.77, 82.23, 110.00 50.8, 82.0, 110.2
Resolution (Å) 1.7 2.4
Total no. observations 132,999 79,815
No. unique observations 48,317 18,236
Multiplicity 2.75 4.4
Data completeness (%) 93.8 (90.0) 99.5 (99.8)
No. data 
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ularly residues 116 (8–10, 18) and 114 (11, 12). However,
it is unclear whether class I–peptide loading in the absence
of TAP association predominantly reflects (a) a physical in-
ability to associate with TAP under any circumstances, (b)
competition for TAP by other endogenous class I mole-
cules (7, 22), or (c) efficient peptide capture mechanisms
that preclude further ligand optimization in the PLC. We
have suggested previously that phenotypic variation in as-
sembly and transport of class I molecules reflects a level of
HLA polymorphism shaped by a host advantage in resisting
viral interference with peptide loading (6, 23, 24). Here,
we demonstrate a striking difference in Ag presentation be-
tween HLA-B
 
*
 
4405 and B
 
*
 
4402. These natural HLA-B al-
leles are present in diverse human populations with B
 
*
 
4402
being most common (found in 
 
 
 
11% of caucasians) and
B
 
*
 
4405 being relatively rare (
 
 
 
1%) (25). They differ by
only a single residue at position 116 (B
 
*
 
4402 116D
 
→
 
B
 
*
 
4405 116Y) located in the F pocket of the binding cleft
(26, 27). This amino acid substitution subtly alters the pep-
tide repertoire of the two allotypes, but more importantly
the hydrophobic F pocket of B
 
*
 
4405 is associated with
binding of peptide Ag in the absence of detectable associa-
tion with the PLC. Significantly, this class I–loading phe-
notype is also less susceptible to viral interference with the
supply of peptide Ag.
 
Materials and Methods
 
Cell Lines and Flow Cytometry.
 
721.220 is a human lympho-
blastoid cell line that lacks HLA-A and -B and functional tapasin
(4, 28). Transfection of 721.220 cells with HLA-B gene con-
structs, WT, and soluble human tapasin cDNAs was performed as
described previously (6, 17, 18). The human B lymphoblastoid cell
line Hmy2.C1R is a 
 
 
 
-irradiation mutant that expresses HLA-C
and insignificant levels of endogenous HLA-A2 and B35 (29).
Hmy2.C1R transfected with HLA-B
 
*
 
4402 and HLA-B
 
*
 
4405 has
been described previously (18). Hmy2.C1R transfectants express-
ing either HLA-B
 
*
 
4402 or HLA-B
 
*
 
4405 and ICP47 were created
by transfection of the gene encoding HSV ICP47 (30) into
Hmy2.C1R.B
 
*
 
4402 and Hmy2.C1R.B
 
*
 
4405, respectively. Cell
culture conditions have been described previously (6, 7).
 
Antibodies.
 
HC-10 is a mouse mAb that recognizes free class
I heavy chain and poorly conformed HC–
 
 
 
2M complexes (31,
32). Mouse mAb 148.3 recognizes human TAP-1 (33), and
RING4C is a rabbit antipeptide antibody to the COOH-termi-
nal region of TAP-1 (34). Giles anti-hTsn (a gift from B. Gao,
University of Oxford, Oxford, England, UK) and Rgp48N (a gift
from P. Cresswell, Yale University, New Haven, CT) (14) are
rabbit antipeptide antibodies raised against the NH
 
2
 
 terminus of
human tapasin. For cell surface staining of HLA molecules, the
mAbs W6/32 (pan class I) or RM7.9.63 (anti-Bw4) were used as
primary antibodies.
 
Immunoprecipitations and Western Blots to Assess Protein–Protein
Interactions.
 
Metabolic labeling of cells, immunoprecipitation,
and endoglycosidase H (Endo H) experiments were performed as
described previously (6, 17, 18). After primary immunoprecipita-
tion, immune complexes were washed then boiled in SDS load-
ing buffer (100 C for 10 min), and the cellular proteins (2.25  
106 cells/lane) were separated on a 10% SDS-PAGE gel before
immunoblotting with biotinylated HC-10, RING4C, or Giles
anti-hTsn antibodies to detect either class I heavy chain, TAP, or
tapasin, respectively. Either HRP-conjugated StreptAvidin (Chemi-
con) or sheep anti–rabbit Ig (Silenus) was used as a secondary Ab,
and proteins were visualized using Renaissance chemilumines-
cence substrate (NEN).
Purification of Cell Surface-associated HLA-B44 Complexes and
Peptide Analysis. Purification of HLA-B*4402 and B*4405 was
performed from 5   109 C1R.B*4402 and C1R.B*4405 cells
grown in roller bottles, and peptides were recovered as described
previously (23). Peptides were separated by RP-HPLC using a
SMART system HPLC (Pharmacia Biotech) with a  RPC C2/
C18 column (2.1 mm [inside diameter]   10 cm) and characterized
by matrix-assisted laser desorption/ionization time of flight mass
spectrometry (MALDI-TOF MS) as described previously (23, 35).
Crystallization, Data Collection, and Structure Determination.
Complexes of B*4405–EEFGRAFSF and B*4403–EEPTVIKKY
were prepared from Escherichia coli, refolded, and crystallized with
the indicated peptide as described previously (35, 36). The data
were processed and scaled using the HKL package (37). The
structures were refined using our previously defined B*4402
structure as a starting model (35). The progress of refinement was
monitored by the Rfree value (3% of the data) with neither a
sigma, nor a low resolution cut off being applied to the data. The
structures were refined using the simulated-annealing protocol
implemented in CNS (version 1.0) (38). The electrostatic surfaces
of the area bounding the F pocket of B*4402 and B*4405 were
depicted using the program GRASP (39). A summary of the data
collection and refinement statistics is given in Tables I and II, re-
spectively. The pdb accession codes are 1SYS and 1SYV.
HSV Infection of Human PBMCs. Human PBMCs (3   106
HLA-A2, 29, B*4402, Cw5 and A2, 26, B*4405, 55, Cw2, 3)
were inoculated with either HSV-KOS (multiplicity of infec-
tion   4) or with PBS (mock control) in 900  l serum-free
RPMI 1640 for 1 h at room temperature with occasional mixing.
PBMCs were subsequently resuspended in medium containing
human serum and incubated for 12, 24, 36, 48, 56, and 72 h at
37 C, 5% CO2 before flow cytometric analysis.
Online Supplemental Material. Supplemental material pro-
vides experimental results of TAP peptide translocation assays,
expression data for soluble human tapasin transfections, pulse–
chase experiments on ICP47 transfectants, metabolic labeling ex-
periments to demonstrate class I–TAP association, a table of con-
tacts between DP  peptide and B*4405, results of peptide elution
experiments, and B*4405 expression in the TAP-deficient T2 cell
line. Figs. S1–S7 and Tables S1 and S2 are available at http://
www.jem.org/cgi/content/full/jem.20031680/DC1.
Results
HLA-B*4405 (116Tyr) but not HLA-B*4402 (116Asp) Is
Expressed on the Surface of Tapasin-deficient Cells. Surface
expression of B*4402 is highly dependent on interaction
with human tapasin in mouse cells (17) and in tapasin-defi-
cient human 721.220 cells (6). In contrast, HLA-B*4405
containing a single substitution at position 116 (B*4402
116D→B*4405 116Y) is expressed at high levels on the cell
surface of mouse L cells and in the 721.220 cell line. Culture
of transfected cells at 26 C stabilizes poorly loaded class I
molecules permitting their transport to the cell surface. Ac-
cordingly, HLA-B*4402 showed almost 10-fold enhance-
ment of cell surface expression at 26 C compared with cul-HLA Polymorphism Controls Ag Presentation Pathway 16
ture at 37 C (Fig. 1 A). Culture of B*4405  L cells or
721.220 transfectants at 26 C did not improve cell surface
expression of B*4405, indicating that B*4405 molecules
were already loaded with peptides in these cells. Moreover,
introduction of the human tapasin gene into L cells or
721.220 transfectants rescued surface expression of B*4402
by  10-fold, whereas tapasin expression made no significant
difference to surface levels of B*4405 (Fig. 1 A). In tapasin-
deficient cells, the surface expression of B*4405, but not
B*4402, was associated with intact Ag presentation of en-
dogenous virus-specific determinants to CTL (unpublished
data), consistent with Ag presentation by B*2705 in tapasin-
deficient cells (6). These data demonstrate that unlike B*4402
molecules, HLA-B*4405 retains the capacity for cell surface
expression and Ag presentation in cells lacking functional
tapasin, a molecule essential for formation of the PLC.
HLA-B*4405 Is not Detectable in the TAP-associated
PLC. HLA-B*2705 molecules can also load with pep-
tides in the absence of any association with TAP (6, 23);
however, in the presence of endogenous tapasin, some
B*2705 is incorporated into the PLC and undergoes opti-
mization of its peptide cargo (6, 18). Thus, we evaluated
whether B*4405 is also associated with the PLC in cells ex-
pressing tapasin. HLA class I heavy chain was not detected
in any of the TAP complexes from cells lacking tapasin,
verifying the documented role of tapasin in bridging class
I–TAP complexes (14, 21) (Fig. 2 A), nor was class I heavy
chain identified in the 721.220 cell line expressing human
tapasin (.220.hTsn) reflecting the absence of HLA-A and
-B. Prolonged exposure of immunoblots revealed a faint
band corresponding to normal levels of background HLA-C
complexed to TAP in these cells (not depicted). In con-
trast, in the presence of tapasin class I heavy chains were
present in TAP complexes from 721.220 cells expressing
B*4402 and B*2705, but not in cells expressing B*4405 de-
spite the presence of tapasin. This observation was con-
firmed in the class I–deficient lymphoblastoid cell line C1R
expressing B*4405, where only very low levels of endoge-
nous class I heavy chains were detected in longer exposures
of immunoblotted TAP complexes, reflecting the defect in
HLA-A and -B expression by these cells (Fig. 2 B). Al-
though B*4405–TAP complexes were not detectable in
C1R cells, there was a significant increase in class I heavy
chains detected above background in TAP complexes from
C1R cells expressing B*4402 (Fig. 2 B). The mAb HC-10
recognizes free class I heavy chains and heavy chains that
are poorly assembled with  2M such as those present in the
PLC (32). Therefore, we examined HC-10 immunopre-
cipitates from C1R transfectants for the presence of any as-
sociated TAP (Fig. 2 C) or tapasin (Fig. 2 D). TAP1 mole-
cules were efficiently coprecipitated with B*4402 but were
barely detectable in immune precipitates from B*4405-pos-
itive C1R cells (Fig. 2 C). Similarly, an association of tapa-
sin with B*4405 could not be detected above the endoge-
nous C1R background in class I immune precipitates from
C1R.B*4405 cells but was detected in C1R.B*4402 cell
lysates (Fig. 2 D). In metabolic labeling experiments, there
were no detectable TAP-associated class I heavy chains
above the background of HLA-C molecules in B*4405-
transfected 721.220.tapasin or C1R cells (Fig. S1, available
at http://www.jem.org/cgi/content/full/jem.20031680/
DC1). Together, the data are consistent with either very
short-lived or negligible incorporation of B*4405 mole-
cules into the PLC.
Rapid Intracellular Transport of B*4405 versus B*4402 Mol-
ecules. Tapasin retains nascent class I molecules in the ER
(13, 17, 40) but B*4405 is transported rapidly to the cell
surface (41) consistent with its capacity to acquire peptide
cargo in the absence of detectable association with the PLC.
Hence, we compared the intracellular transport kinetics of
B*4402 and B*4405 in the 721.220 and C1R cell lines.
Pulse-chased class I molecules were examined for their ma-
turity by digestion with Endo H to distinguish between im-
mature, Endo H–sensitive (Fig. 3, s) proteins in the ER and
mature, Endo H resistant (Fig. 3, r) proteins that have tran-
sited the Golgi. In tapasin-deficient 721.220 cells, B*4402
Figure 1. HLA-B*4405 (Tyr 116) but not B*4402 (Asp 116) is ex-
pressed on the surface of cell lines deficient in human tapasin. (A) Mouse
L cells expressing human  2m (J26) and either the human cell line
721.220 (.220) or transfectants expressing human tapasin (.220.hTsn)
were stably transfected with genes encoding either B*4402 or B*4405 and
then stained by indirect immunofluorescence with mAb W6/32 (anti-
HLA class I) after culture overnight at 26 C (solid lines) or 37 C (bold
dotted lines). Flow cytometric histograms also show background staining
of untransfected J26 and 721.220 cells (thin dotted lines) and conjugated
antibody alone (shaded). (B) Expression of human tapasin (hTsn) was ver-
ified in immunoblots of the indicated cell lysates probed with a specific
rabbit antiserum.Zernich et al. 17
molecules fail to load with peptide resulting in their low
surface expression and degradation (6). However, B*4405
molecules do load with peptide in the 721.220 cells where
their rate of acquisition of Endo H resistance was as rapid in
the absence of tapasin as for B*4402 molecules in the pres-
ence of tapasin (Fig. 3 A). In tapasin-positive 721.220 cells,
the transport of B*4405 molecules was even faster com-
pared with B*4402 molecules (compare the ratio of ‘r’ and
‘s’ at 70 min [Fig. 3 A]). Similar relative maturation kinetics
were observed in C1R cells that express endogenous HLA-C,
which matures very slowly and is stably associated with
TAP (42). Hence, in C1R cells Endo H–resistant class I
molecules were detected at 20 min in the B*4405 transfec-
tants versus 45 min in the B*4402 transfectants (Fig. 3 B,
compare lanes 1, 4, and 7). Interestingly, tapasin expression
accelerates the maturation and transport of B*4405 mole-
cules in the 721.220 transfectants (Fig. 3 A, compare 20
min time points B*4405 with or without tapasin). We rea-
soned that this enhancement might be due to the increase
in peptide translocation after tapasin expression in 721.220
Figure 2. No detectable incorporation of HLA-B*4405 into the PLC.
(A) Cell lysates (lysate) or TAP immune complexes formed with anti-mAb
148.3 mAb (TAP IP) were immunoblotted for the presence of class I
heavy chains using biotinylated HC-10 (anti–class I hc). Untransfected
721.220 cells (untrans) and cells transfected with the indicated genes were
compared. (B) Class I–reduced (C1R) B-LCLs expressing either B*4402
or B*4405 were assayed as in A. A prolonged exposure (5 min) of the blot
is shown to demonstrate the association of low levels of endogenous HLA-C
class I heavy chain with the TAP complex (bottom). (C) Cell lysates (lysate)
or class I heavy chain complexes formed with mAb HC-10 (hc IP) were
then immunoblotted for the presence of TAP-1 using anti–TAP-1 rabbit
antiserum. Immunoblotted lysates of the C1R cells and TAP-negative cell
T2 are shown as controls (right). (D) Cell lysates (lysate) or class I heavy
chain complexes (hc IP) from C were immunoblotted for the presence of
tapasin using anti-hTsn rabbit antiserum. The parental 721.220 (.220) and
721.220.hTsn (.220.hTsn) transfectants are shown as controls.
Figure 3. Rapid maturation and transport of HLA-B*4405 compared
with HLA-B*4402. Cellular proteins from the indicated 721.220 transfec-
tants expressing or lacking membrane tapasin (A), C1R cells (B), and the
indicated 721.220 transfectants expressing or lacking soluble tapasin (C)
were labeled with 35S-Met/Cys for 5 min and chased for 20, 45, and 70
min before immunoprecipitating class I/ 2M molecules with mAb W6/
32. Immune complexes were treated with Endo H to determine the pro-
portion of mature, Endo H–resistant (r), or post-Golgi proteins versus the
immature, Endo H–sensitive (s), or ER proteins by SDS-PAGE and fluo-
rography. In the C1R.B*4405 transfectants, there is an additional band of
unknown origin migrating faster than the class I proteins. This appears to
be a clone-specific background band that is not observed in anti–class I
Western blots.HLA Polymorphism Controls Ag Presentation Pathway 18
strong preference for Phe in the F pocket of B*4405 (Table
S1, available at http://www.jem.org/cgi/content/full/
jem.20031680/DC1). Analysis of the peptide repertoire by
MALDI-TOF mass spectrometry revealed some peptides
were unique to each allotype, but overall there was a sub-
stantial overlap in the peptides eluted from B*4405 and
B*4402 (Fig. 4). This was confirmed in a fraction by frac-
tion analysis (not depicted) and is reminiscent of the subtle
impact of F pocket polymorphism on the peptide reper-
toire of HLA-B27 subtypes (44, 45).
We next determined the structure of HLA-B*4405 com-
plexed with EEFGRAFSF, an abundant shared ligand de-
rived from HLA-DP , and compared this with the structure
of B*4402/EEFGRAFSF (35) (Fig. 5). A detailed descrip-
tion of the structures including amino acid contacts is given
in Table S2 (available at http://www.jem.org/cgi/content/
full/jem.20031680/DC1). The polymorphism at 116 (Tyr
to Asp) significantly impacts on the characteristics of the re-
spective F pockets (Fig. 5, A–F). The H-bond networks in-
volving residue 116 and the arrangement of aromatic resi-
dues in the F pockets of B*4402 and B*4405 are shown in
Fig. 5, B and C, respectively. In B*4402, the presence of
Asp 116 imparts a markedly electronegative potential on the
F pocket (Fig. 5 E), whereas in B*4405 the F pocket is pre-
dominantly hydrophobic (Fig. 5 F). Nonetheless, the speci-
ficity, mode of P9-Phe binding, and architecture of the F
pocket is largely maintained in the two structures (Fig. 5, B
and C). The basis for the alternate selection of either Phe or
Tyr in the F pocket of B*4402 was addressed by analyzing a
new structure of B*4403 complexed to the natural peptide
ligand EEPTVIKKY (Fig. 5 D). Both B*4402 and B*4403
have Asp at position116 and are virtually identical in their F
pockets (35). In the B*4403–P9 Tyr complex, the carbox-
ylate of Asp 116 formed a H-bond with the P9 TyrO  group
(Fig. 5 D). Accordingly, a tyrosine would be much less fa-
vorable within the B*4405 F pocket as this polar P9 TyrO 
group will not be satiated, thus explaining the bias to Phe at
P9 in the B*4405 peptide repertoire.
Resistance of B*4405 Molecules to TAP Blockade by the
HSV Inhibitor ICP47. The ability of B*4405 molecules to
load with peptides in cells lacking tapasin suggested that
nascent B*4405 may acquire peptide very efficiently, thus
averting the normal ER retention mechanisms that opti-
mize peptide loading. Given the very short half-life of pep-
tides in the ER (46), this property of B*4405 could have
advantages under conditions of limiting peptide supply or
disruption of the PLC by pathogen-encoded molecules
(47, 48). We tested this idea by examining the impact of
the Herpes simplex TAP inhibitor, ICP47 (30), on surface
expression of B*4402 and B*4405. Expression of ICP47
markedly reduced peptide delivery to the ER in the trans-
fectants, but notably, it was not completely abolished in ei-
ther cell line (Fig. S4, available at http://www.jem.org/
cgi/content/full/jem.20031680/DC1). Although peptide
supply was comparably impaired in the B*4405 and B*4402
transfectants, cell surface expression of B*4402 on C1R
cells was almost completely abolished, whereas B*4405 ex-
pression was reduced by 10–30-fold in the presence of
Figure 4. Overlapping peptide repertoires but altered P9 anchor pref-
erence in B*4402 and B*4405. Comparison of B*4402 and B*4405 peptide
repertoires by MALDI-TOF mass spectrometry. Total peptide eluates
from HLA-B*4402 (positive polarity spectra) and HLA-B*4405 (negative
polarity spectra) after a single dimension chromatographic separation. The
masses of prominent species are shown. Pool Edman sequence analysis of
peptides eluted from HLA-B*4402 and B*4405 revealed dominant anchor
residues at P2Glu and P9Tyr/Phe. Phe and Tyr were recovered in equal
amounts from P9 of B*4402, but Phe was predominant at this position in
B*4405 (Phe:Tyr   4:1; see Table S1)
transfectants (Fig. S2, available at http://www.jem.org/cgi/
content/full/jem.20031680/DC1) or to an influence of
free tapasin on B*4405 molecules (16). Therefore, we
examined the effect of soluble tapasin on the kinetics of
B*4405 maturation (Fig. S3, available at http://www.jem.
org/cgi/content/full/jem.20031680/DC1). Although solu-
ble tapasin does not bridge TAP and class I proteins or in-
crease TAP expression (16), its expression enhanced the
maturation of B*4405 in 721.220 cells to much the same
extent as WT tapasin (Fig. 3 C) consistent with a role for
tapasin in optimizing peptide cargo independently of the
PLC (16, 43). However, peptide optimization of B*4405
even in the presence of tapasin was only partial compared
with B*4402 (18). We conclude that although B*4405 is
not incorporated into the PLC there is some interaction
with free tapasin. The lack of detectable tapasin association
with B*4405 in Fig. 2 D suggests a low affinity for this in-
teraction consistent with the detergent-sensitive nature of
the PLC (14, 21).
Substitution of 116Asp (B*4402)→116Tyr (B*4405) Biases
the P9 Side Chain Preference and Creates a Hydrophobic F
Pocket in B*4405. To better understand the impact of the
polymorphism at 116Asp (B*4402)→116Tyr (B*4405), we
compared the peptides eluted from B*4402 and B*4405
molecules expressed by C1R cells. The overall recovery of
peptides and their ionization intensity was greater for
B*4402 than B*4405 (Fig. 4), consistent with the failure of
B*4405 to fully optimize its cargo in the PLC (18).
Whereas the B pocket preference for P2-Glu was con-
served between B*4402 and B*4405, the preference at P9
in the F pocket was not identical in these allotypes. Edman
sequencing of pooled peptide eluate from B*4402 con-
tained equal amounts of phenylalanine or tyrosine at P9,
but in B*4405 the ratio of Phe:Tyr was 4:1, suggesting aZernich et al. 19
ICP47 (Fig. 6 A). There was significant improvement in
B*4405 but not B*4402 expression after culture of cells at
26 C, reflecting further stabilization of suboptimally loaded
molecules (Fig. 6 A). Similar results were observed in mul-
tiple independent ICP47 transfectants (not depicted).
The peptides loaded by B*4405 in the presence of
ICP47 were TAP dependent since surface expression of
B*4405 was minimal in the TAP-deficient cell line T2 and
peptides eluted from B*4405 transfectants expressing
ICP47 largely overlapped with those eluted from C1R cells
expressing B*4405 without ICP47 (Figs. S5 and S6,
available at http://www.jem.org/cgi/content/full/jem.
20031680/DC1). We conclude that B*4405, but not
B*4402, can capture ligands under drip feed conditions of
peptide delivery due to TAP blockade.
Expression of ICP47 also resulted in reduced steady-state
levels of intracellular B*4402 and B*4405 heavy chains
(Fig. 6 B) that were mostly retained in the ER or degraded
due to impaired peptide supply (references 6, 49; Fig.
S7, available at http://www.jem.org/cgi/content/full/jem.
20031680/DC1). Retention of peptide-starved B*4405
could involve interaction with calnexin (32), calreticulin
(14), or free tapasin (50, 51). Peptide starvation by ICP47
did not drive the association of nascent B*4405 and the
PLC but significantly increased the proportion of B*4402
molecules bound to TAP (Fig. 6 C). These findings imply
that B*4405 is structurally unsuited to incorporation into
the PLC, even under the stress of limiting peptide supply,
and suggests rapid capture of peptides through a PLC-inde-
pendent pathway. This feature of B*4405 is likely to make
Figure 5. The structure of HLA-B*4405 alters peptide specificity and increases hydrophobicity in the F pocket. (A) Overview of the structure of
B*4405 highlighting Tyr116 and the electron density of the peptide (Dp 46-54, EEFGRAFSF). The structure of the F pocket in HLA-B*4402/EEFGRAFSF
(B) (35) and the new structures B*4405/EEFGRAFSF (C) and HLA-B**4403/EEPTVIKKY (D) are shown as ball and stick representations of F pocket
amino acids (gray), residue 116 (yellow), and the peptide ligand (green), including the COOH-terminal peptide residue P9 Phe in B and C and P9 Tyr
in D. Dotted lines are H bonds. The  2-helix has been removed for clarity. In the B*4402 structure (B), Asp 116 is part of an intricate polar network in-
volving Asp 114, Asp 156, Arg 97, and several conserved water molecules that additionally bridge contacts to the bound peptide. Asp 116 is orientated in
the same direction as the aromatic ring of Tyr 116 in the B*4405 structure. A water molecule fills the “cavity” at position 116 of B*4402 such that it su-
perposes closely to Tyr 116 O  group in B*4405 and forms a similar role in that it bridges one H bond to Asp 114. In B*4405 (C), the P9 anchor residue Phe
projects into a hydrophobic F pocket where it is surrounded by the aromatic rings of Tyr 74, Tyr 116, Tyr123, and Trp 147, as well as making van der
Waals contacts with Ile 95 and the aliphatic moiety of Asn77. The main chain of this COOH-terminal residue is tethered by H bonds to Asn77, Tyr84,
and Thr143. Tyr 116 forms the base of this pocket, where the aromatic ring points away from the F pocket, such that the Tyr 116 O  group points to-
ward the P7 pocket where it forms two H bonds with the Asp 114 carboxylate, an H bond to Arg 97 N , and additionally forms a water-mediated H bond
to the backbone of the bound peptide (Phe 7N). The aromatic ring of Tyr 116 also packs against the long aliphatic side chain of Arg 97. The electrostatic
surfaces of the area bounding the F pocket of B*4402 (E) and B*4405 (F) are depicted using the program GRASP(39). Electropositive (blue); electro-
negative (red).HLA Polymorphism Controls Ag Presentation Pathway 20
it less susceptible to pathogen evasion mechanisms that im-
pair peptide supply or that interfere with components of
the PLC. We tested this idea further by monitoring the
surface expression of B*4402 and B*4405 in PBMCs in-
fected with HSV in vitro (Fig. 7). Infection of PBMCs
with HSV resulted in an early up-regulation of surface class
I expression, presumably due to induction of cytokines like
IFN . However, there was also significant down-regula-
tion of surface class I molecules in the infected cell popula-
tion (10–15% cells; Fig. 7, arrows), initially evident at 24 h
and persisting for 36–48 h postinfection. Although there
was a 5–10-fold down-regulation of surface B*4402, the
effect on surface B*4405 was barely detectable over the
same period. The findings confirm that HLA-B*4405 mol-
ecules are relatively unaffected by interference with TAP
function during HSV infection and suggest that B*4405
will have low susceptibility to diverse viral evasion strate-
gies that disrupt the PLC.
Discussion
In this study, we provide evidence that the functional
consequences of some class I polymorphisms extend beyond
modulating peptide specificity to substantially affect the ge-
neric pathway of Ag presentation. Our findings focus on a
natural polymorphism of HLA-B44 but are applicable to
other class I polymorphisms showing variable incorporation
into the PLC during Ag presentation (4–6, 8–12, 18). Al-
though incorporation of HLA-B*4405 into the PLC is not
detectable, free tapasin appears to partially optimize the pep-
tide cargo of B*4405 molecules similar to the rat class I mol-
ecule RT1-Au which loads peptides even when excluded
from the TAP complex by competition with RT1-Aa (43).
The differences in Ag presentation pathways used by
B*4402 and B*4405 are controlled by a single residue at po-
sition 116 (Asp→Tyr). Although the peptide repertoire of
HLA-B*4405 and B*4402 is overlapping, both allotypes
present some unique peptides. The choice of P9 anchor res-
idue (Phe or Tyr) in B*4402 is more constrained in B*4405
(Phe) largely because Asp116 on the floor of the B*4402 F
pocket can H bond with P9 Tyr. However, this effect in
Figure 6. Expression of the HSV TAP inhibitor ICP47 differentially
impairs cell surface expression of HLA-B*4402 versus B*4405. (A) Cell
surface expression HLA-B*4402 and B*4405 by C1R transfectants in the
presence and absence of ICP47. Cells were stained by indirect immunofluo-
rescence for the shared Bw4 determinant after culture at 37 C (bold dotted
lines) or 26 C (solid lines). Flow cytometric histograms include staining of
untransfected cells (thin dotted lines) and conjugate alone (filled histo-
grams). (B) Steady-state total HLA–class I heavy chain expression in C1R
transfectants   ICP47. Immunoblots using mAb HC-10 were performed
on graded cell numbers of transfectants. (C) Lack of detectable B*4405
within the TAP-associated PLC of C1R transfectants expressing ICP47.
TAP complexes were immunoprecipitated from C1R transfectants express-
ing either B*4402 or B*4405   ICP47 using mAb 148.3. Immunoprecip-
itates were subsequently immunoblotted for the presence of class I hc us-
ing biotinylated HC-10 and developed as described in Fig. 2.
Figure 7. Infection of primary
lymphocytes with HSV differen-
tially down-regulates surface ex-
pression of B*4402 versus B*4405.
Human PBMCs from B*4402-
and B*4405-positive donors were
inoculated with HSV-KOS at an
multiplicity of infection of 4.
PBMCs were then stained with
biotinylated anti-Bw4 (solid lines)
followed by streptavidin APC at
the indicated time points after
inoculation. Flow cytometric
histograms include staining of
mock-infected cells (thin dotted
lines). One of two independent
experiments is shown. The ar-
rows show the population of in-
fected cells with reduced class I
expression. The experiment
shown used WT HSV for infec-
tion to exclude artifacts from the
 -gal–tagged virus that was used
in other experiments to define
the infected cells.Zernich et al. 21
B*4405 is a bias toward peptides with a P9 Phe rather than
exclusion of peptides with a P9 Tyr. The differences in P9
anchor specificity and the natural repertoire of peptides
bound by B*4402 and B*4405 are comparable to the re-
ported differences between B*2705 and B*2709 which dif-
fer by Asp116→His116 (45). Ag presentation by B*4402 is
highly dependent on tapasin, which is essential for the re-
cruitment of class I molecules into the PLC (6, 17). Accord-
ingly, B*4402 molecules bind TAP and undergo substantial
optimization of their peptide cargo (18). In contrast, B*4405
molecules do not associate with the PLC and undergo only
partial optimization in the presence of tapasin (18). HLA-
B*4405 molecules are rapidly transported to the cell surface
(41) and the average thermostability of B*4405–peptide
complexes expressed by lymphoblastoid cells is lower than
those expressed by B*4402 (18). This finding reflects the
more efficient PLC-mediated optimization of peptide cargo
in B*4402 versus B*4405 (18, 23, 51).
The ability of B*4405 to capture limiting peptides with-
out being incorporated into the PLC is associated with de-
creased electronegativity and increased hydrophobicity of
the F pocket arising from the Asp116→Tyr116 substitu-
tion. Nonpolar interactions drive class I–peptide association
(52) and are generally unfavorable at solvent-exposed sites
(53), so the Tyr at position 116 will exacerbate the need to
satiate the hydrophobic F pocket of B*4405. Thus, the hy-
drophobic F pocket (Tyr 74, Tyr 116, Tyr 123, Trp 147,
Ile 95, and the aliphatic moiety of Asn 77) is shielded from
solvent when occupied by P9 Phe. The stacking interac-
tion between the side chains of aromatic residues can con-
tribute between 1.3 and 6 kcal/mol to protein stability
(54). This property of the F pocket in B*4405 will signifi-
cantly reduce the entropic penalty of peptide ligation com-
pared with that of B*4402, predicting more favorable
assembly kinetics of B*4405 and perhaps explaining the
tapasin dependence of B*4402. Of note, recombinant
B*4405 assembles more efficiently with the EEFGRAFSF
peptide ligand than B*4402 (not depicted). A critical role
for F pocket hydrophobicity in controlling peptide capture
is also suggested by the tapasin independence of in vitro
mutants at F pocket residue 114 of class I molecules (11,
12), natural allotypes of HLA-B15 that differ at residue 116
(8, 10), and site-directed mutants at residue 116 of HLA-
B7 (8). However the overall architecture of the F pocket
probably determines whether hydrophobically driven pep-
tide ligation is the sole mechanism of acquiring peptides
under limiting conditions (9).
The loading of peptide into the class I molecule initiates
the folding of “open” class I molecules into their final con-
formation (32). Initial binding of peptide may involve liga-
tion of the COOH terminus, thus creating folding interme-
diates suitable for NH2-terminal peptide trimming (55, 56),
or peptide exchange. Hence, peptide loading might resemble
a zipper, or a venus fly-trap (15), that closes from the peptide
COOH terminus to NH2 terminus. In this model, any
chemical advantage in the trapping and stabilization of pep-
tide through the F pocket structure might be critical in con-
trolling tapasin dependence. Interestingly, the structural
changes in the F pocket of B*4405 also appear to abrogate its
incorporation into the PLC, a tapasin-dependent process (13,
21), raising the possibility that in addition to other binding
sites tapasin interacts with the F pocket of class I molecules.
Our data suggests that B*4405–peptide complexes as-
semble very efficiently leading to rapid egress of loaded
molecules from the ER rendering them relatively resistant
to viral evasion mechanisms that target the conventional
loading pathway. Viral interference with Ag presentation is
widespread, and several viral proteins specifically affect the
incorporation of class I molecules with the PLC (24, 57–
59). Adenovirus E19 protein may inhibit tapasin function
and retain some molecules in the ER (58), and cytomega-
lovirus US3 protein impairs class I expression by interfering
directly with tapasin (24, 48, 60). The mouse   Herpes vi-
rus also appears to subvert class I molecules assembled in
the PLC (47) while simultaneously orchestrating the degra-
dation of tapasin and TAP (59). Viral proteins such as HSV
ICP47 can also impair peptide supply to the PLC (30);
therefore, we used HSV ICP47 to probe the loading capa-
bilities of B*4405 and B*4402 under the stress of limiting
peptide supply. HLA-B*4405 was far more efficient at pre-
serving Ag presentation under ICP47 blockade. These
findings were observed both in transfected cell lines and
during HSV infection of primary lymphocytes. The find-
ings highlight the advantage of the B*4405 loading path-
way that ligates peptides without incorporation into the
PLC, allowing some degree of continued Ag presentation
despite peptide starvation. By contrast, B*4402 molecules
sustain much lower surface expression under the same
“drip-feed” conditions of peptide supply. This feature of
B*4405, and other allotypes that can load without incorpo-
ration into the PLC, might be particularly important dur-
ing competition for the TAP complex by multiple class I
allotypes (7). The capacity to capture peptides without in-
corporation into the PLC would permit Ag presentation by
those class I molecules, whereas slow class I allotypes com-
plexed with the PLC selfishly optimized their peptide Ag
(43). HLA-B*4402 and B*4405 appear to represent polar-
ized extremes within a much broader spectrum of tapasin
dependence in HLA class I allotypes (5). HLA-B27 ex-
presses an increased number of “empty” molecules on the
cell surface (61–63), suggesting that some B27 molecules
load suboptimally without incorporation into the loading
complex (6), whereas others interact with the TAP com-
plex and create very stable complexes (18). In contrast,
HLA-B8 is more dependent on the loading complex for
proper peptide presentation but not as much as B*4402 (6,
21). This HLA variation suggests that as well as diversifying
epitope specificities class I polymorphism presents a tanta-
lizing evolutionary choice for the host. On the one hand,
class I allotypes that are incorporated into the PLC undergo
efficient ligand optimization but are at greater risk of viral
interference, whereas class I allotypes that can still load
without incorporation into the PLC may optimize their
cargo inefficiently but are less susceptible to viral evasion.HLA Polymorphism Controls Ag Presentation Pathway 22
The ancient nature of tapasin (64), and its role in the re-
finement of peptide loading by class I molecules (13),
implies that this gene function has been highly selected
through evolution. Therefore, complete independence from
the PLC in the case of B*4405 may be unusual, since it
comes at a significant cost to the host, perhaps being se-
lected by rare pathogen determinants (7) or specific viral
evasion mechanisms such as the tapasin inhibitors CMV
US3 (24) or adenovirus E3/19Kd protein (65). This might
explain the “schizophrenia” of known tapasin-independent
class I allotypes that are actually incorporated into the PLC
and undergo peptide optimization in the presence of tapa-
sin but can still load peptides in its absence (6, 7, 43). The
evolutionary cost of a high degree of independence from
the PLC might be tolerated in hosts expressing a functional
mixture of class I allotypes (1).
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